Attovia Therapeutics (ATTO) CBO reports 103,269 shares plus major option grants
Rhea-AI Filing Summary
Attovia Therapeutics, Inc. reported the initial equity holdings of Chief Business Officer Zaneta Odrowaz. She directly holds 103,269 shares of common stock, including 17,156 unvested shares that continue to vest monthly and are scheduled to be fully vested on April 27, 2027, subject to continued service. She also holds stock options to purchase common stock, including options over 15,137 shares at $1.5793 per share expiring on August 16, 2033, 5,382 shares at $2.8799 expiring on March 5, 2034, 102,260 shares at $3.5302 expiring on May 8, 2034, and 85,037 shares at $4.9237 expiring on May 17, 2035. Each option vests over four years, with 25% vested on specified initial vesting dates and the remaining shares vesting in equal monthly installments over three years, contingent on continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
Odrowaz Zaneta
Role
Chief Business Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) F2 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F3 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F4 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F5 | -- | -- | -- |
| holding | Common Stock F1 | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 207,816 shares (Direct);
Common Stock — 103,269 shares (Direct)
Footnotes (5)
- F1. As of the date of this Form 3, 17,156 shares are unvested. The remaining shares will continue to vest monthly and will be fully vested on April 27, 2027, subject to continued service to the Issuer through each vesting period.
- F2. The option vests over a four-year period. The vesting schedule is as follows: 25% of the shares underlying the option vested on August 17, 2024, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the reporting person's continued service to the Issuer on each vesting date.
- F3. The option vests over a four-year period. The vesting schedule is as follows: 25% of the shares underlying the option vested on March 6, 2025, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the reporting person's continued service to the Issuer on each vesting date.
- F4. The option vests over a four-year period. The vesting schedule is as follows: 25% of the shares underlying the option vested on May 9, 2025, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the reporting person's continued service to the Issuer on each vesting date.
- F5. The option vests over a four-year period. The vesting schedule is as follows: 25% of the shares underlying the option vested on May 18, 2026, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the reporting person's continued service to the Issuer on each vesting date.
Key Figures
Common shares held: 103,269 shares
Unvested common shares: 17,156 shares
Option underlying shares (1.5793): 15,137 shares
+3 more
6 metrics
Common shares held
103,269 shares
Directly owned Attovia common stock as reported by Zaneta Odrowaz
Unvested common shares
17,156 shares
Unvested portion of common stock, fully vesting by April 27, 2027
Option underlying shares (1.5793)
15,137 shares
Underlying common shares for option at $1.5793, expiring August 16, 2033
Option underlying shares (2.8799)
5,382 shares
Underlying common shares for option at $2.8799, expiring March 5, 2034
Option underlying shares (3.5302)
102,260 shares
Underlying common shares for option at $3.5302, expiring May 8, 2034
Option underlying shares (4.9237)
85,037 shares
Underlying common shares for option at $4.9237, expiring May 17, 2035
Key Terms
Form 3, beneficial ownership, Stock Option (Right to Buy), underlying security, +1 more
5 terms
Form 3 regulatory
"As of the date of this Form 3, 17,156 shares are unvested."
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
beneficial ownership regulatory
"Initial statement of beneficial ownership of securities by reporting person."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy) with underlying common stock."
underlying security financial
"underlying security title listed as Common Stock for each option."
vesting schedule financial
"The option vests over a four-year period. The vesting schedule is as follows:"
A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What equity stake did Attovia Therapeutics (ATTO) disclose for Zaneta Odrowaz?
Attovia reported that Chief Business Officer Zaneta Odrowaz directly holds 103,269 shares of common stock. This includes vested and 17,156 unvested shares that continue to vest monthly through April 27, 2027, subject to continued service.
What stock options for Attovia (ATTO) common stock does Zaneta Odrowaz hold?
She holds options over 15,137 shares at $1.5793, 5,382 shares at $2.8799, 102,260 shares at $3.5302, and 85,037 shares at $4.9237 per share. These options relate to Attovia common stock and have expiration dates between 2033 and 2035.
What are the expiration dates of Zaneta Odrowaz’s Attovia (ATTO) stock options?
Her reported options expire on August 16, 2033, March 5, 2034, May 8, 2034, and May 17, 2035. Each grant covers different share amounts and exercise prices but all reference Attovia common stock as the underlying security.
How do Attovia (ATTO) stock options granted to Zaneta Odrowaz vest?
Each option grant vests over four years. 25% of the underlying shares vested on the specified initial vesting date for each grant, with the remaining 75% vesting in equal monthly installments over the next three years, contingent on continued service.
Does the Form 3 for Attovia (ATTO) show insider buying or selling by Zaneta Odrowaz?
The Form 3 is an initial ownership report and lists holdings and option grants for Zaneta Odrowaz. It does not report buy or sell transactions; it simply discloses her existing positions as of the reporting date.